NEW YORK — Celsius Therapeutics said today that it has signed an agreement to help Johnson & Johnson subsidiary Janssen Biotech identify drug response biomarkers for an investigational ulcerative colitis drug combination.
NEW YORK — Celsius Therapeutics said today that it has signed an agreement to help Johnson & Johnson subsidiary Janssen Biotech identify drug response biomarkers for an investigational ulcerative colitis drug combination.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.
Privacy Policy. Terms & Conditions. . Copyright © 2021 GenomeWeb, a business unit of Crain Communications. All Rights Reserved.